Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2014 Jan;11(1):24-37. doi: 10.1038/nrclinonc.2013.208. Epub 2013 Nov 19.

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.

Author information

1
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA.

Abstract

Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving tumours. Although vaccine approaches have had some clinical success, most cancer vaccines fail to induce objective tumour shrinkage in patients. More-recent approaches have centred on a series of molecules known as immune checkpoints-whose natural function is to restrain or dampen a potentially over-exuberant response. Blocking immune checkpoint molecules with monoclonal antibodies has emerged as a viable clinical strategy that mediates tumour shrinkage in several cancer types. In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types.

PMID:
24247168
PMCID:
PMC4086654
DOI:
10.1038/nrclinonc.2013.208
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center